PreveCeutical Medical Inc.
PRVCF
$0.0145
-$0.0005-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 629.70K | 561.20K | 488.50K | 601.00K | 538.60K |
| Depreciation & Amortization | 7.40K | 7.30K | 7.30K | 7.20K | 10.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 699.80K | 637.10K | 564.50K | 676.90K | 614.80K |
| Operating Income | -699.80K | -637.10K | -564.50K | -676.90K | -614.80K |
| Income Before Tax | -996.30K | -928.80K | -835.90K | -943.10K | -386.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.00 | -0.93 | -0.84 | -0.94 | -0.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -996.30K | -928.80K | -835.90K | -943.10K | -386.10K |
| EBIT | -699.80K | -637.10K | -564.50K | -676.90K | -614.80K |
| EBITDA | -692.50K | -629.90K | -557.20K | -669.60K | -604.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.14B | 2.14B | 2.14B | 2.14B | 2.13B |
| Average Diluted Shares Outstanding | 2.14B | 2.14B | 2.14B | 2.14B | 2.13B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
